8 research outputs found
Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state.
In order to interpret bone turnover markers (BTMs), we need to establish healthy reference intervals. It is difficult to establish reference intervals for older women because they commonly suffer from diseases or take medications that affect bone turnover. The aims of this study were: (1) to identify diseases and drugs that have a substantial effect on BTMs; (2) to establish reference intervals for premenopausal and postmenopausal women; and (3) to examine the effects of other factors on BTMs in healthy postmenopausal women. We studied women aged 30-39 years (n=258) and women aged 55-79 years (n=2419) from a five-European centre population-based study. We obtained a nonfasting serum and second morning void urine samples at a single baseline visit. BTMs were measured using automated immunoassay analysers. BTMs were higher in patients with vitamin D deficiency and chronic kidney disease. Three or more BTMs were higher in women who were osteoporotic and at least two BTMs were lower in women who were oestrogen replete, taking osteoporosis treatments or having diseases known to affect bone turnover. These were used as exclusion criteria for selecting the populations for the reference intervals. The reference intervals for BTMs were higher in postmenopausal than premenopausal women. Levels of BTMs were not dependent on geographical location and increased with age
A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) – European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people
Towards a dynamic earthquake risk framework for Switzerland
Scientists from different disciplines at ETH Zurich are developing a dynamic, harmonised, and user-centred earthquake risk framework for Switzerland, relying on a continuously evolving earthquake catalogue generated by the Swiss Seismological Service (SED) using the national seismic networks. This framework uses all available information to assess seismic risk at various stages and facilitates widespread dissemination and communication of the resulting information. Earthquake risk products and services include operational earthquake (loss) forecasting (OE(L)F), earthquake early warning (EEW), ShakeMaps, rapid impact assessment (RIA), structural health monitoring (SHM), and recovery and rebuilding efforts (RRE). Standardisation of products and workflows across various applications is essential for achieving broad adoption, universal recognition, and maximum synergies. In the Swiss dynamic earthquake risk framework, the harmonisation of products into seamless solutions that access the same databases, workflows, and software is a crucial component. A user-centred approach utilising quantitative and qualitative social science tools like online surveys and focus groups is a significant innovation featured in all products and services. Here we report on the key considerations and developments of the framework and its components. This paper may serve as a reference guide for other countries wishing to establish similar services for seismic risk reduction.</p
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
Changes of the bone formation marker PINP correlated positively with
improvements in vertebral strength in men with glucocorticoid-induced
osteoporosis (GIO) who received 18-month treatment with teriparatide,
but not with risedronate. These results support the use of PINP as a
surrogate marker of bone strength in GIO patients treated with
teriparatide.
Introduction To investigate the correlations between biochemical markers
of bone turnover and vertebral strength estimated by finite element
analysis (FEA) in men with GIO.
Methods A total of 92 men with GIO were included in an 18-month,
randomized, open-label trial of teriparatide (20 mu g/day, n=45) and
risedronate (35 mg/week, n=47). High-resolution quantitative computed
tomography images of the 12th thoracic vertebra obtained at baseline, 6
and 18 months were converted into digital nonlinear FE models and
subjected to anterior bending, axial compression and torsion. Stiffness
and strength were computed for each model and loading mode. Serum
biochemical markers of bone formation (amino-terminal-propeptide of type
I collagen [PINP]) and bone resorption (type I collagen cross-linked
C-telopeptide degradation fragments [CTx]) were measured at baseline,
3 months, 6 months and 18 months. A mixed-model of repeated measures
analysed changes from baseline and between-group differences. Spearman
correlations assessed the relationship between changes from baseline of
bone markers with FEA variables.
Results PINP and CTx levels increased in the teriparatide group and
decreased in the risedronate group. FEA-derived parameters increased in
both groups, but were significantly higher at 18 months in the
teriparatide group. Significant positive correlations were found between
changes from baseline of PINP at 3, 6 and 18 months with changes in FE
strength in the teriparatide-treated group, but not in the risedronate
group.
Conclusions Positive correlations between changes in a biochemical
marker of bone formation and improvement of biomechanical properties
support the use of PINP as a surrogate marker of bone strength in
teriparatide-treated GIO patients
A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open To access publisher's full text version of this article click on the hyperlink at the bottom of the pagePrevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) - European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. (C) 2016 Published by Elsevier Masson SAS